Table 2.
Multivariable Analyses
| Immunogenicity Outcome | Variable | Time Point | |||||
|---|---|---|---|---|---|---|---|
| 1 mo After 1st Dose | 1 mo After 2nd Dose | 3 mo After 2nd Dose | |||||
| β Estimate (95% CI) | P | β Estimate (95% CI) | P | β Estimate (95% CI) | P | ||
| RBD IgG, log10 international units | age, per y | −.011 (−.017 to −.0055) | .0001 | −.0090 (−.014 to −.0044) | .0002 | −.0080 (−.012 to −.0039) | .0002 |
| Male sex | −.068 (−.25 to .12) | .5 | −.11 (−.27 to .053) | .2 | .044 (−.097 to .18) | .5 | |
| White ethnicity | −.062 (−.25 to .12) | .5 | .063 (−.095 to .22) | .4 | .17 (.031 to .31) | .02 | |
| No. chronic conditions, per additional | −.10 (−.19 to −.0073) | .03 | −.047 (−.12 to .028) | .2 | −.070 (−.14 to −.0038) | .04 | |
| Spikevax vaccine | .26 (−.83 to .60) | .1 | .20 (−.059 to .46) | .1 | .15 (−.088 to .39) | .2 | |
| Sampling date, per da | −.012 (−.047 to .023) | .5 | .0040 (−.027 to .035) | .8 | .0036 (−.021 to .028) | .8 | |
| Dosing interval, per db | NA | … | −.0016 (−.0050 to .0017) | .3 | −.0017 (−.0046 to .0013) | .3 | |
| ACE2 competition, log10 units | Age, per year | −.0016 (−.0040 to .00088) | .2 | −.0053 (−.0096 to −.00093) | .02 | −.0039 (−.0071 to −.00069) | .02 |
| Male sex | −.094 (−.18 to −.011) | .03 | −.068 (−.22 to .082) | .4 | .019 (−.095 to .13) | .7 | |
| White ethnicity | −.046 (−.13 to .035) | .3 | −.098 (−.25 to .051) | .2 | .064 (−.047 to .17) | .3 | |
| No. chronic conditions, per additional | −.015 (−.056 to .026) | .5 | −.029 (−.10 to .042) | .4 | −.028 (−.081 to .026) | .3 | |
| Spikevax vaccine | .098 (−.052 to .25) | .2 | .12 (−.12 to .37) | .3 | .15 (−.049 to .34) | .1 | |
| Sampling date, per da | .0064 (−.0091 to .022) | .4 | −.0070 (−.036 to .022) | .6 | −.000058 (−.0023 to .0024) | > .99 | |
| Dosing interval, per db | NA | … | .0019 (−.0012 to .050) | .2 | −.0069 (−.027 to .013) | .5 | |
| Viral neutralization, log2 reciprocal dilution | Age, per y | −.0080 (−.013 to −.0030) | .002 | −.032 (−.048 to −.016) | .0002 | −.025 (−.040 to −.0095) | .002 |
| Male sex | −.079 (−.25 to .090) | .4 | −.36 (−.92 to .21) | .2 | .11 (−.43 to .65) | .7 | |
| White ethnicity | .0078 (−.16 to .17) | .9 | −.14 (−.70 to .42) | .6 | .25 (−.28 to .78) | .3 | |
| No. chronic conditions, per additional | .049 (−.034 to .13) | .2 | −.056 (−.32 to .21) | .7 | −.16 (−.41 to .097) | .2 | |
| Spikevax vaccine | .40 (.014 to .79) | .04 | .75 (−.17 to 1.67) | .1 | .38 (−.54 to 1.32) | .4 | |
| Sampling date, per da | .0077 (−.024 to .039) | .6 | .022 (−.088 to .13) | .7 | −.071 (−.17 to .023) | .1 | |
| Dosing interval, per db | NA | … | .0024 (−.0094 to .014) | .4 | −.00088 (−.012 to .010) | .9 | |
Statistically significant P values (< .05) are highlighted using bold text.
Abbreviations: CI, confidence interval; IgG, immunoglobulin G; NA, not applicable; RBD, receptor-binding domain.
Day of specimen collection following last dose.
Days elapsed between first and second vaccine dose (where applicable).